4-Hydroxy-5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-3H-1,3-thiazol-2-one (BioDeep_00000185299)
human metabolite blood metabolite
代谢物信息卡片
化学式: C20H19N3O4S (397.1096)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4=C(NC(=O)S4)O
InChI: InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,24H,9,11H2,1-2H3,(H,22,25)
描述信息
同义名列表
3 个代谢物同义名
4-hydroxy-5-({4-[(6-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl)methoxy]phenyl}methyl)-2,3-dihydro-1,3-thiazol-2-one; 4-hydroxy-5-({4-[(6-methoxy-1-methyl-1,3-benzodiazol-2-yl)methoxy]phenyl}methyl)-3H-1,3-thiazol-2-one; 4-Hydroxy-5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-3H-1,3-thiazol-2-one
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- H S Chou, K E Truitt, J B Moberly, D Merante, Y Choi, Y Mun, A Pfützner. A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus.
Diabetes, obesity & metabolism.
2012 Nov; 14(11):1000-9. doi:
10.1111/j.1463-1326.2012.01631.x. [PMID: 22686944] - A P S Kong, A Yamasaki, R Ozaki, H Saito, T Asami, S Ohwada, G T C Ko, C K Wong, G T C Leung, K F Lee, C Y Yeung, J C N Chan. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.
Diabetes, obesity & metabolism.
2011 Sep; 13(9):806-13. doi:
10.1111/j.1463-1326.2011.01411.x. [PMID: 21492364] - Minoru Uchiyama, Haruo Iwabuchi, Fujiko Tsuruta, Koji Abe, Makoto Takahashi, Hiroko Koda, Minoru Oguchi, Osamu Okazaki, Takashi Izumi. Pharmacokinetics, metabolism, and disposition of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys.
Drug metabolism and disposition: the biological fate of chemicals.
2011 Apr; 39(4):653-66. doi:
10.1124/dmd.110.036194. [PMID: 21177486] - Aki Hiuge-Shimizu, Norikazu Maeda, Ayumu Hirata, Hideaki Nakatsuji, Kouichi Nakamura, Akira Okuno, Shinji Kihara, Tohru Funahashi, Iichiro Shimomura. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
Arteriosclerosis, thrombosis, and vascular biology.
2011 Apr; 31(4):792-9. doi:
10.1161/atvbaha.110.221747. [PMID: 21233451] - Salvatore Salomone. Pleiotropic effects of glitazones: a double edge sword?.
Frontiers in pharmacology.
2011; 2(?):14. doi:
10.3389/fphar.2011.00014. [PMID: 21687509] - Shoichi Kanda, Ryutaro Nakashima, Kanako Takahashi, Jun Tanaka, Junko Ogawa, Tsuneaki Ogata, Makoto Yachi, Kazushi Araki, Jun Ohsumi. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
Journal of pharmacological sciences.
2009 Oct; 111(2):155-66. doi:
10.1254/jphs.09084fp. [PMID: 19809220] - Shashank Rohatagi, Timothy J Carrothers, Jinyan Jin, William J Jusko, Tatiana Khariton, Joseph Walker, Kenneth Truitt, Daniel E Salazar. Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs.
Journal of clinical pharmacology.
2008 Dec; 48(12):1420-9. doi:
10.1177/0091270008323260. [PMID: 18936283]
